Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial).

[1]  Emmanuel L Barbier,et al.  Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective , 2020, Science Advances.

[2]  P. Brown,et al.  Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  O. Tillement,et al.  EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles , 2020, Theranostics.

[4]  O. Tillement,et al.  Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol , 2019, BMJ Open.

[5]  J. Flickinger,et al.  Guidelines for Multiple Brain Metastases Radiosurgery. , 2019, Progress in neurological surgery.

[6]  P. Wust,et al.  Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma , 2018, Radiation Oncology.

[7]  Sandeep Jain,et al.  Palliation of Brain Metastases: Analysis of Prognostic Factors Affecting Overall Survival , 2018, Indian journal of palliative care.

[8]  Carri Glide-Hurst,et al.  Evaluation of a magnetic resonance guided linear accelerator for stereotactic radiosurgery treatment. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Yan Liu,et al.  Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells , 2018, Theranostics.

[10]  Ruth E Langley,et al.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial , 2016, The Lancet.

[11]  O. Tillement,et al.  Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[12]  O. Tillement,et al.  MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection. , 2016, Nanomedicine.

[13]  Ross Berbeco,et al.  Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial , 2016, Theranostics.

[14]  Thierry Bastogne,et al.  Nanoparticles for Radiation Therapy Enhancement: the Key Parameters , 2015, Theranostics.

[15]  L. Deangelis,et al.  Treatment of Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wolfgang A Tome,et al.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Perriat,et al.  Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment , 2014, Cancer Nanotechnology.

[18]  S. Anant,et al.  Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer , 2013 .

[19]  R. Weichselbaum,et al.  New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology , 2013, Science Translational Medicine.

[20]  Jean-Luc Coll,et al.  Ultrasmall rigid particles as multimodal probes for medical applications. , 2011, Angewandte Chemie.

[21]  Thierry Epicier,et al.  Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. , 2011, ACS nano.

[22]  P. Brown,et al.  The effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients with breast cancer and brain metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Glenn R. Dickson,et al.  Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles , 2011, Scientific reports.

[24]  L. Recht,et al.  Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. , 2009, International journal of radiation oncology, biology, physics.

[25]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[26]  J. Jolles,et al.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.

[27]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[28]  N. Bleehen,et al.  A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.